POTELLIGENT
LIVE

Serial Number

78219523

Owner

KYOWA KIRIN CO., LTD.

Attorney

Kaushal R. Odedra

Filing Date

Feb 27, 2003

Add to watchlist:

No watchlists yet
View on USPTO

POTELLIGENT Trademark

Serial Number: 78219523 • Registration: 3200292

POTELLIGENT is a trademark filed by KYOWA KIRIN CO., LTD. on February 27, 2003. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). The application is currently registered and active.

Owner Contact Info

KYOWA KIRIN CO., LTD. (47 trademarks)

TOKYO 100-0004 , JP

Entity Type: 03

KYOWA HAKKO KIRIN CO., LTD. (58 trademarks)

1-6-1, OHTEMACHI, CHIYODA-KU
TOKYO , JP

Entity Type: 99

KYOWA HAKKO KOGYO CO., LTD. (51 trademarks)

CHIYODA-KU, TOKYO , JP

Entity Type: 03

Trademark Details

Filing Date

February 27, 2003

Registration Date

January 23, 2007

Published for Opposition

July 25, 2006

Goods & Services

[ Cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives, antacids, hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis, estrogen and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents, cataplasms for the treatment of bruises, lumbago and stiff shoulder, pharmaceutical preparations used to treat hair disorders, anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidium in chickens, and dysentery in pigs, drugs for arteriosclerosis, oncostatic drugs for the treatment for cancer, multienzyme digestants for in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, antiparkinsonism drugs, minor tranquilizers, and antianxiety agents, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system, anti-bacterial preparations, mucolytic preparations, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations, preparations for improving the metabolism and the peripheral circulation, plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, pharmaceutical preparations for the treatment of insomnia and other sleep related diseases ]

[ Cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical research; transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical research ]

Contract manufacturing service in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals

Filing History

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Jan 23, 2026 REM2
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Sep 4, 2019 ASGN
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Mar 17, 2017 NAS8
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Mar 17, 2017 RNL1
REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8
Mar 17, 2017 9G8P
REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED
Mar 17, 2017 8PRT
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 17, 2017 APRE
TEAS SECTION 8 & 9 RECEIVED
Jan 20, 2017 E89R
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - MAILED
Jul 9, 2013 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jul 9, 2013 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jul 9, 2013 APRE
TEAS SECTION 8 & 15 RECEIVED
Jun 23, 2013 E815
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Nov 19, 2008 ASGN
REGISTERED-PRINCIPAL REGISTER
Jan 23, 2007 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Dec 5, 2006 DP1B
NOTICE OF ALLOWANCE CANCELLED
Nov 30, 2006 IUCN
FAX RECEIVED
Nov 30, 2006 FAXX
NOA MAILED - SOU REQUIRED FROM APPLICANT
Oct 17, 2006 NOAM
PUBLISHED FOR OPPOSITION
Jul 25, 2006 PUBO
NOTICE OF PUBLICATION
Jul 5, 2006 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 1, 2006 PREV
ASSIGNED TO LIE
May 26, 2006 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
May 24, 2006 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 24, 2006 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 17, 2006 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 17, 2006 TROA
CONTINUATION OF FINAL REFUSAL MAILED
Apr 28, 2006 CNCF
ACTION CONTINUING A FINAL - COMPLETED
Apr 27, 2006 CNCF
EXAMINERS AMENDMENT MAILED
Apr 27, 2006 CNEA
EXAMINER'S AMENDMENT ENTERED
Apr 27, 2006 XAEC
EXAMINERS AMENDMENT -WRITTEN
Apr 27, 2006 CNEA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 21, 2006 CHAN
FINAL REFUSAL MAILED
Mar 6, 2006 CNFR
FINAL REFUSAL WRITTEN
Mar 3, 2006 CNFR
AMENDMENT FROM APPLICANT ENTERED
Feb 9, 2006 ACEC
PAPER RECEIVED
Feb 7, 2006 MAIL
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 3, 2006 CRFA
PAPER RECEIVED
Feb 3, 2006 MAIL
CORRESPONDENCE MAILED
Oct 18, 2005 CRML
NON-FINAL ACTION WRITTEN
Oct 18, 2005 CNRT
AMENDMENT FROM APPLICANT ENTERED
Sep 26, 2005 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 19, 2005 CRFA
PAPER RECEIVED
Sep 19, 2005 MAIL
LETTER OF SUSPENSION MAILED
May 13, 2005 CNSL
SUSPENSION LETTER WRITTEN
May 12, 2005 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 10, 2005 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 2, 2005 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 2, 2005 TROA
INQUIRY AS TO SUSPENSION MAILED
Nov 22, 2004 CNSI
SUSPENSION INQUIRY WRITTEN
Nov 19, 2004 CNSI
LETTER OF SUSPENSION MAILED
Mar 26, 2004 CNSL
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 9, 2004 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 9, 2004 TROA
NON-FINAL ACTION MAILED
Aug 19, 2003 CNRT
ASSIGNED TO EXAMINER
Aug 14, 2003 DOCK